This video illustrates the key steps involved in the surgical administration of voretigene neparvovec-rzyl (Luxturna), the first FDA-approved gene therapy used for patients affected by biallelic RPE65 mutations. Additionally, surgical pearls and tips for managing challenging portions of the procedure are offered. These techniques are applicable to any substance delivered to the subretinal space, a drug delivery site that will likely be utilized with increasing frequency in the future.